Zofran Lawsuit Alleges Drug Exposure Caused Infant Girl’s Fatal Heart Defect

November 21, 2015 – – ZofranLegal.com reports on the details of a tragic lawsuit filed against anti-nausea medication Zofran and manufacturer GlaxoSmithKline which alleges that exposure to the drug while developing in utero caused a mother’s infant daughter to be born with fatal heart defects, and, subsequently, to pass away after just 11 weeks of life.

Details from the suit state that the mother was prescribed Zofran to combat nausea associated with morning sickness during the first trimester of her pregnancy. The first trimester of pregnancy is also a time when the fetus’ heart does much of its developing. After using Zofran during the pregnancy, the mother gave birth to a baby girl with her heart on the right side of her body rather than the left. The heart was found to have several major defects and the young girl was placed on life support machines while awaiting a heart transplant surgery. After 11 weeks in the NICU, the infant passed away.

The mother’s complaint is filed in the U.S. District Court for the State of Tennessee in the Middle District of Nashville, and is under case number 3:15-cv-00958. Since this initial filing, the case was transferred to Boston, Massachusetts during MDL consolidation. Sadly, the mother is not alone in her allegations. Across the U.S., many mothers have stepped forward with similar allegations. In lawsuits filed against Zofran, the birth defects most commonly connected to the drug are: cleft lip and palate, atrial septal defect and ventricular septal defect, transposition of the greater vessels, tetralogy of fallot, clubfoot, and kidney defects. The suits of these women have been consolidated in a single courtroom in Boston, Massachusetts.

One of the topics most commonly discussed in connection with Zofran birth defect lawsuits is the fact that the drug was never FDA-approved to treat pregnant women, or tested for safety on this consumer group. The United States Food and Drug Administration specifically approved Zofran to treat patients suffering from severe nausea and vomiting after undergoing chemotherapy, radiation, or anesthesia. Despite this fact, however, plaintiffs allege that GSK marketed the drug “off-label” to expectant mothers and Ob/Gyn’s nation-wide. Subsequently, it is prescribed “off-label” to an estimated 1 million pregnant women annually.

As the Zofran MDL cases await trial, many expect that others will continue to appear. The attorneys at Monheit Law believe that there may be many other families who are eligible to file Zofran birth defect lawsuits of their own, and who may be entitled to compensation. They are currently offering free consultations to those who used Zofran while pregnant and who subsequently gave birth to children with defects.

To get additional information on Zofran lawsuits, or to ask questions, please contact Michael Monheit, Esq. of Monheit Law by calling (877) 620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005622